Vemurafenib-induced eccrine squamous syringometaplasia.
Dermatology
; 226(4): 362-4, 2013.
Article
en En
| MEDLINE
| ID: mdl-23860306
We report herein a patient treated with vemurafenib for a stage IV melanoma who developed an eruption related to eccrine squamous syringometaplasia (ESS). This entity is a well-described side effect of cytostatic therapies used for malignant neoplasia and is clinically characterized by a symmetric cutaneous eruption composed of papules and vesicles preferentially located on fold and intertriginous areas. It is histologically defined by a squamous metaplasia of eccrine ductal epithelium. ESS represents another skin eruption to be added to the list of cutaneous adverse events associated with vemurafenib, a selective BRAF inhibitor used to treat patients with metastatic melanoma harboring the V600E mutation. The discussion focuses on the pathogenesis of ESS secondary to vemurafenib and on alternative diagnoses.
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Neoplasias Cutáneas
/
Sulfonamidas
/
Erupciones por Medicamentos
/
Glándulas Ecrinas
/
Células Epiteliales
/
Indoles
/
Melanoma
/
Antineoplásicos
Límite:
Adult
/
Humans
/
Male
Idioma:
En
Revista:
Dermatology
Asunto de la revista:
DERMATOLOGIA
Año:
2013
Tipo del documento:
Article
País de afiliación:
Francia
Pais de publicación:
Suiza